Trial · NCT05796791
Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
NCT05796791, Early phase 1, Completed, Medical University of South Carolina; results first posted 2025-07-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder. Trials, record NCT05796791. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05796791
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
- NCT number
- NCT05796791
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 7 participants, actual
- Lead sponsor
- Medical University of South Carolina
- Conditions
- Tobacco Use, Smoking Cessation, Nicotine Dependence
- Interventions
- Ketamine Hydrochloride, Motivational enhancement therapy
- First posted
- 2023-04-04
- Last updated
- 2025-07-18
- Results first posted
- 2025-07-18
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility of Ketamine Treatment for Tobacco Use Disorder | 8 weeks | The primary outcome of this study will be the feasibility of using ketamine-assisted treatment for smoking cessation, which will assess the number of people selected for randomization that complete the full treatment. This will help determine if the treatment of ketamine in tobacco use would be beneficial for further study. |
| Secondary | Smoking Cessation | Baseline, Treatment week 1, 2, 3, and follow up week 4, and 8 | Saliva cotinine levels will be collected prior to each ketamine session and at each follow up to detect smoking over approximately the past 6 days |
| Secondary | Reduction in Cigarettes Smoked Per Day | Baseline, Treatment week 1, 2, 3, and follow up week 4, and 8 | Evaluate if there is reduction in cigarettes smoked per day via the self-reported time-line follow back |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Feasibility of Ketamine Treatment for Tobacco Use Disorder | 8 weeks | Number of participants enrolled that completed all three interventional sessions. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Smoking Cessation | Baseline, Treatment week 1, 2, 3, and follow up week 4, and 8 | |||
| SECONDARY | Reduction in Cigarettes Smoked Per Day | Baseline, Treatment week 1, 2, 3, and follow up week 4, and 8 |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Feasibility of Ketamine Treatment for Tobacco Use Disorder | Treatment of Tobacco Use Disorder With Ketamine | 7 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment of Tobacco Use Disorder With Ketamine | 7 | |
| Overall Study | COMPLETED | Treatment of Tobacco Use Disorder With Ketamine | 7 | |
| Overall Study | NOT COMPLETED | Treatment of Tobacco Use Disorder With Ketamine | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment of Tobacco Use Disorder With Ketamine | 0 | 7 |
| Total, other adverse events | Treatment of Tobacco Use Disorder With Ketamine | 0 | 7 |
| Total, serious adverse events | Treatment of Tobacco Use Disorder With Ketamine | 0 | 7 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05796791
GET https://conductscience.org/api/trials/v1/NCT05796791/registered